News

October 8, 2014 — Miracor Medical Systems announced that results from the prospective multicenter safety and feasibility study, ‘Prepare RAMSES,’ were presented at the annual Transcatheter...

St. Vincent Implant Thoratec Corp. HeartMate III VAD

St. Vincent Heart Center officials announced that the faith-based hospital is the second in the nation to implant the new investigational “heart pump.”

October 1, 2014 — Heart Hospital of Austin is the first facility in Texas to implant a new miniaturized, wireless monitoring sensor to manage heart failure (HF). The CardioMEMS HF system...

heartmate III, tohratec, heart failure, heart failure treatment

Thoratec Corporation announced that it has begun to enroll patients in the HeartMate III U.S. clinical trial. 

VADs Gain Popularity Artificial Hearts Remain Ideal GlobalData

Robert Littlefield, MSc, GlobalData's senior analyst covering Medical Devices, said: “Since the first implantation of the Jarvik 7 in 1982, artificial heart devices have evolved significantly...

Unexpected trips to the hospital are inconvenient and worrisome for anyone, but for congestive heart failure sufferers, they can be all too frequent.

BioControl Medical Enrollment INOVATE-HF Study CardioFit System Heart Failure

BioControl Medical announced that it has reached an important clinical trial milestone, reaching 480 randomized subjects — or 70 percent — of the planned 650 subjects with congestive...

Geneia announced a multi-year, strategic partnership with Covidien to help improve the health of and reduce the costs for chronically ill patients. 

Medtronic AdaptResponse Global Clinical Trial Cardiac Resynchronization Therapy

Medtronic Inc. announced the first implants in a clinical trial that will compare patient and healthcare system outcomes — including patient mortality and hospitalizations — in ...

September 10, 2014 — ResMed announced results from a study presented at the 2014 European Society of Cardiology (ESC) Congress in Barcelona, Spain, looking at the use of the at-home, contactless,...

September 9, 2014 — Use of a quadripolar left ventricular (LV) lead instead of a bipolar option during cardiac resynchronization therapy (CRT) can decrease complications at six months, according...

stem cells, cytori, stem cell therapy

The Cardiovascular Cell Therapy Research Network (CCTRN), has selected Cytori Therapeutics, Inc. to supply adipose-derived regenerative cells (ADRCs) for a clinical trial aimed at...

September 2, 2014 — Boston Scientific has released the primary endpoint results from its NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) clinical trial, the first and only randomized sham-...

August 28, 2014 — Medtronic Inc. announced the U.S. Food and Drug Administration (FDA) approval of its newest cardiac resynchronization therapy-pacemaker, Viva CRT-P, for indicated patients with...

New data revealing the reduction in cardiovascular (CV) deaths with Novartis' LCZ696 in patients with heart failure with reduced ejection fraction (HF-REF) will be presented at the world's largest...

Sunshine Heart's C-Pulse System Heart Failure Treatment

Sunshine Heart Inc. announced that the current condition of a heart failure patient implanted with the C-Pulse System improved after six weeks of treatment, allowing him to attend his daughter's...

The Healthcare Accreditation Colloquium announced that Texas Children's Hospital has earned the designation of Accredited Pediatric Heart Failure Institute following 12 months of work and an...

MYDICAR Celladon Corp. Clinical Trial Heart Failure Treatments LVADs

Celladon Corp. announced that the first patient has been dosed in a clinical trial titled "Investigation of the Safety and Feasibility of AAV1/SERCA2a Gene Transfer in Patients with Heart Failure...

SynCardia Total Artificial Heart SynHall Valves FDA approval

SynCardia Systems Inc. received approval in July from the U.S. Federal Drug Administration (FDA) for the SynCardia temporary Total Artificial Heart with SynHall valves, giving the company control...

August 7, 2014 — The Berlin Heart Group announced they have completed enrollment in their post-approval study, the only condition of the humanitarian device exemption (HDE) approval that...